Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin
Description of Invention:
The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.
Applications:
In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.
Market:
MS may affect more than 2.5 million people worldwide. Currently, it is estimated that approximately 400,000 Americans are afflicted with MS and 200 more are diagnosed weekly.
Development Status: In vitro and in vivo data are available.
Inventors:
Jacqueline Shukaliak-Quandt et al. (NINDS)
Patent Status:
DHHS Reference No. E-153-2005/0 --
U.S. Provisional Application No. 60/828,735 filed 09 Oct 2006
Licensing Status: Available for non-exclusive or exclusive licensing.
Portfolios: Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Stroke Central Nervous System -Therapeutics-Neurological Therapeutics-Other Central Nervous System -Therapeutics
For Additional Information Please Contact: Norbert J. Pontzer PhD JD
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5502
Email: pontzern@mail.nih.gov
Fax: (301) 402-0220
